Debra represents clients in investigations and litigation related to healthcare, securities and antitrust. A member of the firm's White Collar Litigation and Internal Investigations practice group, Ms. Schreck has experience representing major pharmaceutical and medical device companies in criminal and civil investigations involving allegations of healthcare fraud, including violations of the Food Drug and Cosmetic Act, the Anti-Kickback Statute, and the False Claims Act. She also defends clients in federal and state white collar litigation, including actions brought under the qui tam provisions of the federal False Claims Act and state statutes. Ms. Schreck also advises and assists clients in connection with large-scale internal investigations, internal training programs, and regulatory and compliance issues.

Ms. Schreck serves on the firm's Recruiting Committee and is active in the firm's mentoring program.


  • Bayer Corporation, Bayer HealthCare Pharmaceuticals Inc. and Merck & Co., Inc. in federal and state product liability litigation involving two fluoroquinolone antibiotics, Avelox® and Cipro® (2015 – present).
  • Novartis Pharmaceuticals Corporation and Novartis Corporation in qui tam suit brought in District of Massachusetts by multiple relators, alleging off label and kickback claims in connection with the asthma medication, Xolair®. On a motion to dismiss, obtained dismissal with prejudice of all claims. United States ex rel. Garcia et al. v. Novartis Pharmaceuticals Corporation et al., 06 Civ. 10465 (WGY). Dismissal with prejudice of all federal claims was affirmed by the First Circuit. United States ex rel. Kelly et al. v. Novartis Pharmaceuticals Corporation et al., 827 F.3d 5 (1st Circuit 2016).
  • Major brand name prescription drug manufacturer in qui tam litigation brought in Southern District of New York by government and relator, alleging kickbacks to specialty pharmacies in connection with various medications.
  • International corporation in connection with a pre-merger antitrust investigation by the US Department of Justice, resulting in antitrust clearance.
  • Medical device manufacturer in a multi-district federal investigation involving allegations of off-label promotion and kickbacks.

  • Corporate officer of a technology company in connection with a securities fraud investigation.
  • Government agency official in connection with an ethics probe.


DOJ Gets Practical on Corporate Resolutions: Highlights From Rod Rosenstein's November 29th Comments on Individual Accountability
Qui Notes: Unlocking the False Claims Act
The Devil Is in the Details: Eleventh Circuit Rejects "Insider" Claims and Reaffirms Rule 9(b)'s Requirements
Qui Notes: Unlocking the False Claims Act
Deskbook on Internal Investigations, Corporate Compliance and White Collar Issues (2nd Edition)
PLI Practising Law Institute
DOJ Announces $3.7 Billion in FY2017 False Claims Act Recoveries
SCOTUS Rules on “Implied Certification” Theory of Liability Under Federal False Claims Act


  • JD, Fordham University School of Law, 2006, magna cum laude, Order of the Coif
  • BA, Yeshiva University, 2003, summa cum laude, Valedictorian
  • New York
  • New Jersey
  • US Court of Appeals for the First Circuit
  • US District Court, Southern District of New York
  • US District Court, Eastern District of New York
  • US District Court, District of New Jersey

Email Disclaimer